This study examined the reproducibility of MYC and BCL-2 immunohistochemical scoring as well as the impact of higher expression of both proteins (double expressor status, DE) on survival and progression in a large retrospective cohort of aggressive B-cell lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) or R-CHOP-like regimens with a median follow up of 67 months (range 0–138). We also investigated possible MYC protein expression cut offs with the highest reproducibility among pathologists and predictability of gene translocation. We showed that immunohistochemistry (IHC) for MYC and BCL-2 is highly reproducible when cut-off values of >70% for MYC and >50% for BCL-2 are used. This threshold not only predicts the presence of rearrangements (with respect to MYC), but is also clinically valuable. In fact, it identifies a subset of patients who are poor responders and who may benefit from alternate therapeutic strategies

MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients

Lazzi, Stefano;Zinzani, Pier Luigi;Sabattini, Elena;
2019

Abstract

This study examined the reproducibility of MYC and BCL-2 immunohistochemical scoring as well as the impact of higher expression of both proteins (double expressor status, DE) on survival and progression in a large retrospective cohort of aggressive B-cell lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) or R-CHOP-like regimens with a median follow up of 67 months (range 0–138). We also investigated possible MYC protein expression cut offs with the highest reproducibility among pathologists and predictability of gene translocation. We showed that immunohistochemistry (IHC) for MYC and BCL-2 is highly reproducible when cut-off values of >70% for MYC and >50% for BCL-2 are used. This threshold not only predicts the presence of rearrangements (with respect to MYC), but is also clinically valuable. In fact, it identifies a subset of patients who are poor responders and who may benefit from alternate therapeutic strategies
Ambrosio, Maria R; Lazzi, Stefano; Bello, Giuseppe Lo; Santi, Raffaella; Porro, Leonardo Del; de Santi, Maria M; Guazzo, Raffaella; Mundo, Lucia; Rigacci, Luigi; Kovalchuck, Sofia; Onyango, Noel; Fabbri, Alberto; Cencini, Emanuele; Zinzani, Pier Luigi; Zaja, Francesco; Angrilli, Francesco; Stelitano, Caterina; Cabras, Maria G; Spataro, Giuseppe; Bob, Roshanak; Menter, Thomas; Granai, Massimo; Cevenini, Gabriele; Naresh, Kikkeri N; Stein, Harald; Sabattini, Elena; Leoncini, Lorenzo
File in questo prodotto:
File Dimensione Formato  
e25.full.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione 439.18 kB
Formato Adobe PDF
439.18 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11585/736115
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 18
social impact